NCRI Cancer Conference
2 – 5 October 2005
Birmingham, U.K.

Programme

CME Accreditation
The conference has been approved by
The Federation of the Royal College of Physicians of the UK
for 23 external CPD credits
Event Programme

Sunday 2 October 2005

13.00 – 15.30 Workshops (various)
15.45 – 16.00 Alex Markham (NCRI Chairman)
   Welcome address
16.00 – 16.30 Jessica Corner (UK)
   The future research agenda: the perspective of people affected by cancer
16.30 – 17.10 Rick Kaplan (UK)
   Perspectives on clinical research in the UK versus the US: where are we behind and
   where can we lead?
17.10 – 17.50 Hugues de Thé (FRA)
   Modelling acute promyelocytic leukaemia pathogenesis through therapeutic response
17.50 – 18.30 Adrian Harris (UK)
   New angiogenic pathways regulated by hypoxia
18.30 – 21:00 Opening Reception and Trade Exhibition

Monday 3 October 2005

08.45 – 09.00 Tony Kouzarides (UK)
   Introduction
   Jane Cope (UK)
   Introduction to the NCRI
09.00 – 09.40 William Kaelin (USA)
   The von Hippel-Lindau hereditary cancer syndrome: insights into oxygen sensing and
cancer
09.40 – 10.20 Malcolm Pike (USA)
   Chemoprevention of female cancers in premenopausal women: new targets and
   implementing what we already know
10.20 – 11.00 Coffee and Exhibition Viewing
11.00 – 11.40 Hans Clevers (NED)
   Signalling pathways in the intestine
11.40 – 12.20 Norman Coleman (USA)
   Molecular radiation oncology
12.20 –15.00 LUNCH/Poster Session & Exhibition Viewing
15.00 – 17.15 Parallel Sessions
17.15 – 18.00 BREAK
18.00 – 18.40  Sir David Lane (SNG) – The NTRAC Lecture
Cyclin dependent kinases as targets for cancer therapy

18.40 – 19.20  John Condeelis (USA) – The Institute of Cancer Research Lecture
Discovery and characterisation of an invasion signature for mammary tumour cells

19.30 – 20.30  Civic Reception

20.30  Speakers’ Dinner (By Invitation Only)

Tuesday 4 October 2005

09.00 – 09.40  Mike Richards (UK) – The Hayman Lecture
The contribution that research has made to the development of cancer strategy in the UK

09.40 – 10.20  Réné Bernards (NED)
High throughput loss of function genetic screens to identify cancer-relevant genes

10.20 – 11.00  Coffee and Exhibition Viewing

11.00 – 11.40  Patrick Johnston (UK) – The BACR Tom Connors Lecture
Pharmacogenetics of colorectal cancer

11.40 – 12.20  Sir Richard Peto (UK)
UK cancer mortality trends – The hazards of smoking and benefits of stopping

12.20 – 15.00  LUNCH/Poster Session & Exhibition View

15.00 – 17.15  Parallel Sessions

17.15 – 18.00  BREAK

18.00 – 18.40  Peter Jones (USA)
Epigenetic therapy

18.40 –19.20  Karen Vousden (UK)
Cell death or survival in response to p53

19.30 – 20.30  Drinks Reception

20.30 – 00.00  Conference Dinner & Party

Wednesday 5 October 2005

09.00 – 12.15  Parallel Sessions

CLOSE OF MEETING
PARALLEL SESSIONS

Monday 3rd October

Clinical - Breast Cancer
Hosted by: Bruce Ponder

- Bruce Ponder (UK)
  The search for common predisposing genes
- Kornelia Polyak (USA)
  The tumour microenvironment and its role in breast cancer
- Mary Helen Barcellos-Hoff (USA)
  Emerging roles of TGFbeta in breast cancer
- Andrew Tutt (UK)
  Novel therapy strategies for BRCA1 and BRCA2 associated cancers
- Rob Clarke (UK)
  Isolation and characterization of human mammary stem cells

Consumer Interest - Information - Addressing Patients' Needs
Hosted by: Joanne Rule

- Hilary Thomas (UK)
  Making links - information and the clinical trial
- Speaker to be confirmed
- Roy Grainger (UK)
  Patient information and peer review
- Venetia Franglen
  Case Study – The SUIT Trial of the Impact of Providing Generic Information about Research to Adult Cancer Patients prior to their treatment decision
- David Wright, Mary Sayers and Jenny Walton
  Collaborating with consumers in cancer research: Experience from the Macmillan Listening Study

Therapeutic Development - Developing Drugs Against Oncogenic Proteins
Hosted by: Paul Workman

- Paul Workman (UK)
  Overview and Hsp90 molecular chaperone inhibitors
- Tim Green (UK)
  Pre-clinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530
- Peter Parker (UK)
  Monitoring and targeting signal transduction pathways; EGFR and PI3Kinase
  click here to view the abstract!
- Said Sebti (USA)
  Thwarting Ras and STAT3 aberrant signal transduction circuits to battle cancer
Adam Sharp (UK)
Novel chemical inhibitors of BAG-1 protein: protein interactions inhibit breast cancer cell growth and MAP kinase activity

Cancer Cell Biology - Epigenetics & Methylation
Hosted by: Wolf Reik
- Wolf Reik (UK)
  Imprinting and epigenetic reprogramming in development and disease
- Manuel Esteller (ESP)
  Title to be confirmed
- Dirk Schubeler (SUI)
  Genome-wide and promoter specific analyses reveal sites of differential DNA methylation in normal and transformed human cells
- Charlotte Bradbury (UK)
  Sodium valproate combined with all-trans retinoic acid shows clinical and biological activity in high risk acute myeloid leukaemia
- Richard Bryant (UK)
  The polycomb group protein EZH2 promotes the proliferation and invasion of prostate cancer cells
- Gordon Strathdee (UK)
  HOX gene family members are frequently inactivated by DNA methylation in human leukaemia

Cancer Cell Biology - Metastasis including Stromal Cell Tumour Interactions
Hosted by: Margaret Frame
- Margaret Frame (UK)
  Calpain 2- and Src-dependence define a requirement for integrin turnover during distinct modes of tumour cell invasion
- Peter Friedl (GER)
  Plasticity in cancer invasion: shifting integrin and protease requirements
- Mikala Egeblad (USA)
  Title to be confirmed
- Karin de Visser (NED)
  Inflammation-associated cancer development is B lymphocyte dependent
- Erik Sahai (UK)
  In vivo imaging of squamous cell carcinoma invasion

Clinical - Modern Cancer Screening
Hosted by: Alan Ashworth
- Emanuel Petricoin (USA)
  Use of the low molecular weight range circulatory proteome for biomarker identification: vision for combining with imaging modalities
- Wendy Atkin (UK)
  A new NHS screening programme for bowel cancer screening: challenges and potential rewards
- Julian Peto (UK)
  What cervical cancer screening did
Gareth Williams (UK)
New markers for cancer detection

Jenny Donovan (UK)
Evaluating prostate cancer treatment and the potential impact of screening: The Protect Trial and comparison arm

NCRI Clinical Study Group – Complementary Therapies (note: this parallel session will take place at 12:30 till 17:00)
Hosted by: Susie Wilkinson

12.30 – 12.40 Susie Wilkinson
Introduction

12.40 – 13.05 Janet Richardson/Karen Pilkington
Presentation by Research Council for Complementary Medicine
The long and winding road: Tracking down the evidence in CAM and cancer
Discussion

13.05 – 13.15 Liz Thompson
A randomised, double-blind, placebo controlled, clinical trial to assess the efficacy of the homeopathic medication Stomatect-spray in the prevention of chemotherapy-induced stomatitis in children

13.15 – 13.25 Debbie Sharp
The impact of relaxation and guided imagery training on the symptoms and quality of life in women with ovarian cancer undergoing chemotherapy: a randomised trial

13.25 – 13.35 Kate Thomas
The development and validation of a patient-centred outcome tool for use in cancer support care utilising complementary therapies

13.35 – 13.45 Susie Wilkinson
Helping with Touch or Talk (TOT). A multi-centre randomised controlled trial to examine the clinical and cost-effectiveness of cognitive behaviour therapy, aromatherapy massage and standard care for cancer patients with symptoms of depression and anxiety

13.45 – 13.55 Speaker to be confirmed
Prospective study of safety in acupuncture: patient and practitioner perspectives

13.55 – 14.10 Liz Thompson
Presentation 1 - Homeopathy for symptoms of oestrogen withdrawal in breast cancer survivors- a review of recent trials and the challenge of appropriate research methodologies for complex interventions

14.10 – 14.25 University of Southampton
Presentation 2 - Complementary and alternative therapy use among people undergoing cancer treatment
Discussion

14.25 - 14.40 Debbie Sharp
Presentation 3 - CAM use amongst male cancer patients: reasoned decision-making or ‘clutching at straws’?
Discussion
14.40 – 14.55 **Edzard Ernst**
*Presentation 4 - Ukrain – a new cancer cure? A systematic review of randomised clinical trials*

Discussion

14.55 **Susie Wilkinson**
*Conclusion/Discussion –*

**NCRI Clinical Study Group – Lung Cancer** *(note: this parallel session will take place at 12:30 till 15:00)*
Hosted by: Tim Eisen

12.30 – 12.35 **Tim Eisen**
*INTRODUCTION*

12.35 – 12.45 **Tim Eisen**
*Outcomes of the progress review and restructuring of the group*

12.45 – 13.05 **Tim Eisen**
*Current development and future priorities of the Mesothelioma sub-group*

13.05 – 13.25 **Mike Peake**
*Current development and future priorities of the Sceptre Sub-group*

13.25 – 13.45 **John Field**
*Current development and future priorities of the Tanslational Sub-group*

13.45 – 14.05 **Allan Price**
*Current development and future priorities of the NSCLC Stage I-IIIA SCLC LD Sub-group*

14.05 – 14.25 **David Ferry**
*Current development and future priorities of the NSCLC Stage IIIB/IV SCLC ED Sub-group*

14.25 – 15.00 **Stephen Falk**
*Current development and future priorities of the Rare Tumours Sub-group*

**NCRI Clinical Study Group – Testis Cancer**
Hosted by: Robert Huddart

15.00 – 15.05 **Robert Huddart**
*INTRODUCTION*

**RESULTS OF CLOSED TRIALS**

15.05 – 15.30 **Speaker to be confirmed**
*Final results of MRC TE08: A randomised trial of CT scan-frequency in Stage I NSGCT*

15.30 – 16.00 **Robert Huddart**
*Results of CR UK TE22 trial: A FDG PET in the prediction of relapse in stage I non-seminomatous germ cell tumour*

**NEW RESEARCH / TRIAL IDEAS**

16.00 – 16.30 **Jonathan Joffe**
*UK Management of stage I seminoma. Results of survey and proposals for national trial*

16.30 16.55 **Jonathan Shamash (to be confirmed)**
*Randomised trial – A randomised phase III study of short (30 minute) versus long (72 hour) infusion Bleomycin for patients with IGCCCG good prognosis germ cell tumours, TE3. A NCRI trial*

16.55 – 17.00 **Robert Huddart**
*An overview and discussion of the NCRI testis cancer portfolio*
NCRI Clinical Study Group – Upper GI Cancer
Hosted by: David Cunningham
15.00 – 15.05 David Cunningham
INTRODUCTION
15.05 – 15.35 John Neoptolemos
Current national and international trials in Pancreatic Cancer –
15.35 – 16.05 James Garden (UK)
Current National Trials in Hepatobiliary cancer
16.05 – 16.35 Tom Crosby (UK)
Current Trials of Chemo-radiotherapy in Upper GI Cancer
16.35 – 17.15 Bill Allum
Current National Trials in Oesophago gastric Cancer

Prevention - Hormonal Manipulation
Hosted by: Valerie Beral
- Tony Howell (UK)
  Anti-oestrogens and related therapies to prevent breast cancer
- Henri Rochefort (FRA)
  Markers of response to ovarian hormones in early steps of human mammary carcinogenesis
- Tim Key (UK)
  Endogenous hormones and cancer
- Valerie Beral (UK)
  Potential for preventing cancer in women by hormonal manipulation

Supportive & Palliative Care - Improving the Management of Emotional Distress
Hosted by: Amanda Ramirez
- David Kissane (USA)
  Improving clinical depression in advanced breast cancer: The Spiegel replication RCT
- Michael Sharpe (UK)
  RCT of nurse led intervention for major depression
- Susie Wilkinson (UK)
  RCT of aromatherapy in the management of anxiety and depression
- Amanda Ramirez (UK)
  Poor mental health of cancer consultants

Tuesday 4th October

Clinical - Advances in Pancreatic Cancer
Hosted by: Nick Lemoine
Supported by Pancreatic Cancer Research Fund with CR-UK
- David Tuveson (USA)
  Advances in modelling pancreatic cancer
- Malte Buchholz (GER)
  The diagnostic microchip for pancreatic cancer
- Tatjana Crnogorac-Jurcevic (UK)
  Molecular markers for pancreatic adenocarcinoma
- John Neoptolemos (UK)
  Design and clinical applications of algorithms for early diagnosis
- Margaret Tempero (USA)
  Novel therapeutics – the end of nihilism

**British Oncological Association Session - Future Direction of Radiotherapy**
Hosted by: Robert Coleman and Ros Eeles *(note: this parallel session will take place at 13:00 till 14:45)*

- Norman Coleman (USA) BOA Lecture
  Future role of radiotherapy: the NIH view
- Trevor Roberts (UK)
  The structure of national radiotherapy services for the year 2010
- Peter Hoskin (UK)
  Radiotherapy trials in the UK – is this the renaissance?
- Bleddyn Jones (UK)
  Proton treatment in the UK: Do we really need it?

[Click here for details of full session](#)

**Consumer Interest - Trials to Treatment – should we be getting there quicker?**
Hosted by: Frank Rhodes

- Peter Littlejohns (UK)
  Developing new treatments faster – a research perspective
- Paul Moss (UK)
  Title to be confirmed
- Roger Wilson (UK)
  Case Study – The treatment of GIST

**Cancer Cell Biology - DNA Repair**
Hosted by: Stephen Jackson

- Stephen Jackson (UK)
  The DNA-damage response: from molecular insights towards new approaches to anti-cancer therapy
- Simon Boulton (UK)
  DNA double-strand break repair and cancer predisposition
- Stephen West (UK)
  Homologous recombination and the maintenance of genome stability
- Tomas Lindahl (UK)
  Strategies of repair of alkylated DNA
- Christopher Mathew (UK)
  New genes and protein complexes link Fanconi Anaemia to DNA repair
Clinical - Lung Cancer
Hosted by: Tim Eisen
- Tim Eisen (UK)
  Title to be confirmed
- Rafael Rosell (ESP)
  Predictive markers for customising and targeted therapies
- Roman Thomas (USA)
  Genomic Approaches to Lung Cancer
- Thomas Lynch (USA)
  Targeted Therapy of NSCLC: Role of EGFR TK mutations in selecting agents for treatments

NCRI Clinical Study Group – Colorectal Cancer
Hosted by: John Scholefield

13.30 - 13.35  John Scholefield (UK)
  Welcome and introduction to the aims of this session
13.35 – 13.45  John Scholefield (UK)
  Overview of current trials in portfolio
  HAVE NCRN TRIALS CHANGED PRACTICE?
  QUASAR
13.45 – 13.55  Richard Gray (UK)
  What do the results mean?
13.55 – 14.05  Rob Glynne-Jones (UK)
  What do they mean in terms of changing practice?
  CLASSIC
14.05 – 14.15  Philip Quirke (UK)
  What do the results mean?
14.15 – 14.25  D Morton (UK)
  What do they mean in terms of changing practice?
  FOCUS
14.25 – 14.35  Matt Seymour (UK)
  What do the results mean?
14.35 – 14.45  Will Stewart (UK)
  What do they mean in terms of changing practice?
14.45 – 15.00  Question and answer session
15.00 – 15.20  Tea/Coffee
  NEW TRIALS
15.20 – 15.30  John Primrose (UK)
  FACS relaunch
15.30 – 15.50  Matt Seymour (UK)
  PICCOLO
15.50 – 16.05  Rob Glynne-Jones (UK)
  CHRONICLE
16.05 –16.15  Questions and answer session
NEW DEVELOPMENTS
16.15 – 16.25 David Sebag-Montefiore (UK)
Developments in Rectal Cancer
16.25 – 16.40 What is happening in the Adjuvant Portfolio
David Kerr (UK) (QUASAR 2)
Jim Cassidy (UK) (SCOT)
16.40 – 16.50 Bob Steele (UK)
New developments in prevention, screening and early diagnosis
16.50 – 17.00 John Scholefield (UK)
Closing remarks

NCRI Clinical Study Group – Head and Neck Cancer
Hosted by: Martin Robinson

15.00 – 15.05 Martin Robinson (UK)
Introduction

CURRENT TRIALS
15.05 – 15.05 Martin Robinson (UK)
MARCHON
15.15 – 15.25 Catherine West (UK)
MARCHON - TRANS
15.25 – 15.35 Christopher Nutting (UK)
PARSPORT and HOTTER
15.35 – 15.45 Martin Birchall (UK)
EASTER

THYROID
15.45 – 15.55 Jayne Franklyn (UK)
HILO
15.55 – 16.05 John Buscombe (UK)
Imaging in thyroid cancer

POSSIBLE NEW TRIALS
16.05 – 16.05 J Brown (UK)
Post-operative radiotherapy in head ad neck cancer trial
16.15 – 16.25 K McLennan (UK)
Translational studies
16.25 – 16.35 To be confirmed
Palliative therapy proposal
16.35 – 16.45 Professor McGurk (UK)
Sentinel node biopsy study
16.45 – 17.00 I Hutchinson (UK) (SEND trial)
Speakers to be confirmed
NCRI Clinical Study Group – Melanoma / Renal Cancer
Hosted by: Martin Gore & Barry Hancock
12.30 - 13.00  Tim Eisen (UK)
  Latest news on signal inhibition
13.00 – 13.30  Robert Hawkins (UK)
  Enhancing host responses to immunotherapy
CURRENT TRIALS AROUND THE WORLD
13.30 – 13.45  Dr David Chao (UK) / Professor Martin Gore (UK)
  Melanoma
13.45 – 14.00  Emilio Porfiri (UK) / Professor Barry Hancock (UK)
  Renal Cancer
CURRENT TRIALS IN THE UK
14.00 – 14.15  Martin Gore (UK)
  Melanoma
14.15 – 14.30  Barry Hancock (UK)
  Renal Cancer

NCRI Clinical Study Group – Radiotherapy
Hosted by: Peter Hoskin
15.00 – 15.05  Peter Hoskin (UK)
  Introduction
RADIOThERAPY TRIAL UPDATE
15.05 – 15.20  Christopher Nutting (UK)
  PARSPORT
15.20 – 15.35  John Yarnold (UK)
  FAST/IMPORT (Physics)
15.35 – 15.50  David Dearnaley (UK)
  RT01/CHIPP
15.50 – 16.05  Peter Hoskin (UK)
  BNLI lymphoma dose trial
16.05 – 16.20  D Talbot (UK)
  AQ4N
16.20 – 17.00  Pat Price (UK)
  ACCORN

NCRN Clinical Trials Showcase
Hosted by: Rick Kaplan
  Speakers to be confirmed
Clinical - Ovarian Cancer
Hosted by: Stan Kaye
- Robert Brown (UK)
  Drug resistance in ovarian cancer: obstacle or target?
- Hani Gabra (UK)
  Molecular profiling/gene expression analysis in ovarian cancer and potential for individualised treatment
- Ian Jacobs (UK)
  NCRI screening trials
- Stan Kaye (UK)
  Update on management of ovarian cancer, including novel approaches [click here to view the abstract]
- Julia Wilson (UK)
  Expression of the chemokine receptor CXCR4 alters the behaviour of ovarian cancer cells in vitro and in vivo

Clinical - Paediatric Oncology
Hosted by: Andy Pearson
- Andy Pearson (UK)
  The challenges for clinical trials in childhood cancer and new drug development in the next 5 years
- Javed Khan (USA)
  Inferring tumour progression models using array CGH data
- Nazneen Rahman (UK)
  Aneuploidy-cancer predisposition syndromes - new insights into the links between the mitotic spindle checkpoint and childhood cancer development
- AV Moorman (UK)
  Molecular cytogenetic characterisation of childhood acute lymphoblastic leukaemia (all) and correlation with outcome
- Debbie Graham (UK)
  Mapping and analysis of tumour suppressor genes (TSGs) on chromosome 10q in childhood medulloblastoma
- Aliki Taylor (UK)
  Risk of breast cancer in female survivors of childhood hodgkin’s disease in Britain

Prevention - General, including Screening and Vaccination
Hosted by: Valerie Beral
- Charles Lacey (UK)
  Human Pappilomavirus vaccines against cervical cancer
- Andy Hall (UK)
  Primary liver cancer – prevention by vaccination & aflatoxin reduction
- Sue Moss (UK)
  The potential of screening to prevent cancer deaths in the UK
- Jane Wolstenholme (UK)
  The Economics of Cancer Screening
Cancer Cell Biology - Stem Cells
Hosted by: Fiona Watt
- Sean Morrison (USA)
  Tumour suppressor genes regulate stem cell self-renewal
- Fiona Watt (UK)
  Role of stem cells in epidermal tumour formation.
- Dominique Bonnet (UK)
  Normal and leukaemic stem cells
- Amanda Fisher (UK)
  Epigenetic profiles predict stem cell potency
- Matthew Smalley (UK)
  Molecular dissection of the mouse mammary gland reveals a SCA-1-/CD49F- population which contains cells with stem cell ability

Supportive & Palliative Care - Improving Symptom Management and overall Patient Care
Hosted by: Lesley Fallowfield
- Charles Cleeland (USA)
  Improving symptom management in patients with cancer
- Galina Velikova (UK)
  Routine symptom assessment, subsequent communication and patient well being
- Lesley Fallowfield (UK)
  Effective communication with patients who have cancer
- Irene Higginson (UK)
  Title to be confirmed

Therapeutic Development - Tumour Suppressor Gene and Apoptosis Targets
Hosted by: Herbie Newell
- Herbie Newell (UK)
  Overview of approaches to target tumour suppressor gene loss in cancer
- Lyubomir Vassilev (USA)
  Small-molecule antagonists of the p53-MDM2 interaction: promising new agents for cancer therapy
- Saul Rosenberg (USA)
  Novel antitumour agents that target the Bcl-2 family of antia-poptotic proteins
- Jean-Pierre Issa (USA)
  Title to be confirmed
- Melanie Howell (UK)
  Pharmacological inhibition of NF-KB selectively induces apoptosis in chronic lymphocytic leukaemia cells
Wednesday 5th October

Therapeutic Development - Angiogenesis
Hosted by: Adrian Harris

- Roy Bicknell (UK)
  Identification of novel targets in the tumour vasculature; Robo4
- Gordon Jayson (UK)
  Imaging angiogenesis
- George Sledge, Jr (USA)
  Clinical development of VEGF-targeting agents
- Robert Kerbel (CA)
  Markers and mechanisms for metronomic antiangiogenic chemotherapy
- Emma Rennel (UK)
  VEGF 165b expression inhibits growth of human renal cell carcinomas xenotransplanted into nude mice
- Carolyn Staton (UK) – (BCR Translational Research Award)
  Discovery and development of alphastatin, a novel anti-angiogenic and anti-vascular agent derived from humanfibrinogen

British Oncological Association Session – Integration of radiology in radiotherapy: the promise of image-guided treatment planning
Hosted by: Chris Nutting and Joe O'Sullivan

- QS Ng (UK)
  Tumour anti-vascular effects of Radiotherapy (RT) combined with weekly combretastatin A4 Phosphate (CA4P) compared with RT alone
- RA Sharma (UK)
  Yttrium-90 chemoradiation treatment of liver metastases from colorectal cancer: International phase I trial
- MT Guerrero Urbano (UK)
  Results of Intensity Modulated Radiotherapy (IMRT) in patients with locally advanced thyroid cancer: Report of acute toxicity
- R Singhal (UK)
  Effect of cavity shaving on re-operation rate following breast conserving surgery
- Marcel Van Herk (NED) - The Bob Champion Cancer Trust Lecture
  Image guided radiotherapy: current state of the art
- Pat Price (UK)
  The application of functional imaging to radiotherapy planning
- Christopher Nutting (UK)
  Current status and future role of IMRT

Click here for details of full session
Cancer Cell Biology - Cancer Genetics
Hosted by: Doug Easton
- Doug Easton (UK)
  Title to be confirmed
- Allan Balmain (USA)
  Mouse models for the analysis of human cancer susceptibility
- Michael Stratton (UK)
  Title to be confirmed
- Gerry Thomas (UK)
  The Chernobyl legacy: Relationship between radiation exposure RET rearrangement and BRAF mutation in childhood thyroid cancer
- Paul Wright (UK)
  Identification of oestrogen-regulated genes in human breast cancer cells using DNA microarrays

Consumer Interest - Patients' Debate
Hosted by: Roger Wilson and Alf Oliver
- Alison Eastwood (UK) - Matthew Hallsworth (UK)
  Public Awareness of Cancer Research
- Formal debate: the motion - Placebo has no place in cancer trials
  Proposed by: Keith Taylor (NCRI CLG)  Seconded by: tba
  Against the motion: Fergus Macbeth (UK)  Seconded by: Roger Wilson (UK)
- Ernest Parry (UK), Karen Wilman (UK) and David Ardron (UK), Vivienne Brown (UK) and Phil Cotterell (UK)
  Changing the dynamics of the research culture

Clinical - Gastrointestinal Cancer
Hosted by: David Cunningham
- Janusz Jankowski (UK)
  Preventing cancers of the gastrointestinal tract
- Gina Brown (UK)
  Improving outcomes for patients with rectal cancer
- John Neoptolemos (UK)
  Progress in pancreatic cancer
- David Cunningham (UK)
  Targeted treatments in gastrointestinal cancer

Cancer Cell Biology - Immunology
Hosted by: Peter Johnson
- Peter Johnson (UK)
  Immunostimulatory antibodies
- Thomas Wolfel (GER)
  Targets of the autologous anti-tumour response
Laurence Zitvogel (FRA)
Immunopharmacology promoting NK cell activation for cancer therapeutics

Paul Moss (UK)
Title to be confirmed

Neil Steven (UK)
A novel non-viral transfection system for dendritic cells: results of a pilot trial of vaccination against melanoma antigens

Cancer Cell Biology - Infection and Cancer
Hosted by: Chris Boshoff

Max Parkin (UK)
Cancer: the global contribution of infection

Alan Rickinson (UK)
Immunotherapies for nasopharyngeal carcinoma and Hodgkin's disease

Diane Harper (USA)
A vaccine for cervical cancer

Mary Kroll (UK)
Trends in childhood leukaemia, Britain 1974-98

Andrea Varro (UK)
Role of MMP-7 in epithelial-mesenchymal signalling

Seonaidh Cotton (UK)
Lifestyle factors associated with high-risk HPV infection in women with cervical smear showing bordering nuclear abnormality

Seyyed Rezaee (UK)
Suppression of inflammatory reactions by recombinant KSHV vOX-2:Fc protein

NCRI Clinical Study Group – Breast
Hosted by: Robert Coleman
“Endocrine manipulation for breast cancer prevention and treatment”

9.00 – 9.25 Mitch Dowsett
Targeting targeted therapy in breast cancer

9.25 – 9.50 Ian Smith
Making the best use of aromatase inhibitors in operable breast cancer. Current status and future questions

9.50 – 10.15 Chairs, speakers, Dan Rea and Robert Leonard
Panel discussion

10.15- 10.45 tea / coffee

10.45 – 11.10 Andrew Wardley
Breakthrough of the decade?
First results of Adjuvant and Neoadjuvant trials with trastuzumab (Herceptin)
11.10 – 11.35 Rob Stein
*Herceptin failure in advanced breast cancer: controversies and new clinical trials*

11.35 – 12.00 David Cameron
*Clinical approach to new treatment targets in breast cancer*

12.00 – 12.15 Chairs, speakers, Peter Canney
*Panel discussion*

**Prevention - Behaviour change**
Hosted by: Jane Wardle
- Jane Wardle (UK)
  *Tackling the obesity epidemic*
- Robert West (UK)
  *Projected national smoking prevalence and smoking-related death rates following actual and potential policy initiatives in the UK*
- Gary Whitlock
  *Obesity and premature death: a prospective study of 500,000 men and 300,000 women*
- Peter Boyle (FRA)
  *IARC and cancer control worldwide*

**Clinical - Prostate Cancer**
Hosted by: David Neal
- David Neal (UK)
  *Clinical background to prostate cancer – potential areas for targeting current and future research*
- William Nelson (USA)
  *Early initiation of prostate cancer – potential for chemoprevention*
- Val Macaulay (UK)
  *The IGF axis as potential target for treatment of prostate cancer*
- Ian Mills (UK)
  *Effects of a membrane trafficking protein on androgen response*
- Joe O’Sullivan (UK)
  *A Phase 2 study of high activity Rhenium-186 HEDP with autologous peripheral blood stem cell transplant in progress hormone refractory prostate cancer metastatic to bone*
- Griet Vanpoucke (UK)
  *Identification of mesenchymal genes involved in prostate development and carcinogenesis using serial analysis of gene expression (SAGE)*
Cancer Cell Biology - Radiobiology  
Hosted by: Gillies McKenna

- **John Thacker (UK)**  
  *The influence of DNA repair genes on radiation sensitivity and genetic stability in mammals*

- **Gillian Tozer (UK)**  
  *Tumour vasculature as a target for treatment*

- **Gillies McKenna (USA)**  
  *Signal transduction targets for modifying radiation responses*

- **A Chalmers (UK)**  
  *DNA repair mechanisms underlying the radiosensitising effects of chemical inhibitors of PARP-1*

- **Kaye Williams (UK) - (BACR/AZ Young Scientist Frank Rose Award)**  
  *Combining HIF-1 targeted approaches with conventional anti-cancer treatments*
WORKSHOPS

Sunday 2nd October

NCRI Cancer Informatics Initiative Workshop
Co-Chairs: Richard Begent and Ken Buetow

13.00 – 13.45  Alex Markham
                (Chair, NCRI Informatics High Level Steering Committee, UK)
                Introduction and Welcome

13.15 – 13.45  Ken Buetow
                (Director of NCICB and caBIG programme, USA)
                Cancer Informatics

13.45 – 14.15  Sir Mike Brady
                (Principal Investigator, e-DiaMoND project, UK)
                Medical Imaging

14.15 – 14.45  Carlos Caldas
                (Principal Investigator, CancerGRID project, UK)
                CancerGRID - A Demonstrator for the NCRI Informatics Initiative

14.45 – 15.00  Richard Begent
                (Chair, NCRI Informatics Task Force, UK)
                Title to be confirmed

Molecular Targeting in Cancer
(Sponsored by: The Cancer Recognised Research Group in Northern Ireland and The Research and Development Office of the HPSS NI)
Joint chairs: Stephanie McKeown and Paddy Johnston

13.00 – 13.45  Keynote lecture:
                Steve Jackson
                The Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, UK.
                “Molecular targeting in cancer: lessons from the field of DNA repair”

13.45 – 14.00  Timothy R Wilson, Wendy L Allen, Ultan McDermott, Miranda McEwan, Leena Galligan and
                Patrick G Johnston, Daniel B.Longley
                Drug Resistance Group, Centre for Cancer Research and Cell Biology, Queen’s University
                Belfast, N. Ireland.
                c-FLIP: a new target for colon cancer?

14.00 – 14.15  Andrea Valentine, Hayley McKeen, Helen O. McCarthy, Kerry McAlpine, Keeva McClelland,
                David G. Hirst, Tracy Robson.
                Molecular Therapeutics Group, School of Pharmacy, Queen’s University Belfast, Belfast,
                N.Ireland.
                Characterisation of a novel HSP90 interacting protein, FKBP-L/DIR1; implications for
                pathways controlling cell growth and survival.

14.15 – 14.30  Luciano A. Guerreiro Lucas\textsuperscript{1,2}, Christopher A. Mitchell\textsuperscript{1}, Paul Barber\textsuperscript{2}, Keyi Jiang\textsuperscript{3}, Gerald A.
                Soff\textsuperscript{2}, Gillian M. Tozer\textsuperscript{2}.
                1 Centre for Molecular Biosciences, University of Ulster, Coleraine, N. Ireland;
Molecular targeting of angiogenesis - an intravital imaging study.

Christopher J Watson1, Hugh O'Kane1, Perry Maxwell1,2, Kate E. Williamson1
1 Uro-Oncology Research Group, Department of Pathology, Queen's University Belfast, Northern Ireland
2 Royal Hospitals Trust, Belfast, N. Ireland.
In vitro and in vivo evidence that mitomycin-c chemotherapy up-regulates the death receptor Fas in bladder cancer cells.

Supportive and Palliative Care - Interactive Workshop on Communicating about Randomised Control Trials
Hosted by: Lesley Fallowfield
Speakers to be confirmed

Workshop on Cancer Associated Thrombosis 12.30 – 2pm
Chairmen: Michael Peckham, London Stan Kaye, London

12.15 – 12.45 Collect Japanese lunch-box
12.45 – 12.50 Michael Peckham
Introduction:
12.50 – 13.20 A.K. Kakkar
Prevention and treatment of VTE in cancer
13.20 – 13.40 A Young
Catheter associated thrombosis
13.40 – 13.55 Questions
13.55 – 14.00 Stan Kaye
Closing remarks.

Translational Research in Clinical Trials Workshop
Hosted by: Peter Parker
Supported by CR-UK TRICC in association with NTRAC
- Arul Chinnaiyan (USA)
  The success story: from trial samples to clinical data
- Doug Altman (UK)
  The reality check: statistics and samples
- Emanuel Petricoin (USA)
  Proteomics for clinical applications and molecular medicine
Phil Quirke (UK)
Trials, imaging and pathology

James Brenton (UK)
Clinical significance of functional genomics

Workshop Panel:
– At last the clinical trial is in place – but what samples should I collect and what should I do with them?
Hosted by: Carlos Caldas
Click here for details of full session